Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease
Conditions: Type 2 Diabetes; Chronic Kidney Diseases Interventions: Drug: GLP-1 receptor agonist; Drug: basal insulin Sponsors: LMC Diabetes& Endocrinology Ltd.; Novo Nordisk Canada Inc. Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Canada Health | Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Endocrinology | Insulin | Research | Urology & Nephrology